NATIONAL-TSING-HUA-UNIV
4.3.2020 10:02:08 CET | Business Wire | Press release
Although unmanned aerial vehicles (UAV) are commonly used in the fields such as communications and agriculture, their use is hampered by their small size and limited battery capacity. However, a multi-disciplinary team at National Tsing Hua University led by professors Tang Kea-tiong of the Department of Electrical Engineering and Lo Chung-chuan of the Department of Life Sciences has recently developed an artificial intelligence (AI) chip that mimics the optical nerves of the fruit fly, allowing drones to automatically avoid obstacles while remaining in an ultra-power-saving mode.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200304005029/en/
Most of the UAVs currently in use rely on the transmission and reflection of electromagnetic waves to detect and avoid obstacles, but this consumes a lot of power. An alternative approach to avoiding obstacles is to use optical lenses to capture and analyze images, but the amount of information to be processed is too large to be done quickly, and this approach also consumes much power.
Intrigued by the fruit fly’s uncanny ability to avoid obstacles, Tang figured that it might be possible to replicate the optical nerve of this tiny insect and adapt it to AI applications.
The first task was to solve the problem of information overload. According to Tang, the image sensor currently used in cameras and mobile phones have millions of pixels, whereas the eye of a fruit fly has only about 800 pixels. When the fruit fly’s brain processes such visual signals as contour and contrast, it utilizes a kind of detection mechanism which automatically filters out unimportant information, and only pays attention to moving objects liable to collide with.
By imitating this detection mechanism, the research team has developed an AI chip which makes it possible to use hand gestures and an image sensor to operate a drone.
First the drone is taught to focus on what’s most important, and then it’s taught how to judge distance and the likelihood of a collision. For this purpose, Lo conducted a detailed investigation on how the fruit fly detects optical flow, for which purpose he made extensive use of the maps of the fruit fly’s neural pathways produced by the Brain Research Center at NTHU. “Optical flow is the relative trajectory left in the field of vision by nearby moving objects, and which is used by the brain to determine its distance and to avoid obstacles,” Lo explained.
Tang said that the AI chip developed by his research team represents a major breakthrough in the area of in-memory computing. Computers and mobile phones first move data from the memory to the CPU’s central processing unit, and once it’s processed, the data is moved back to the memory for storage, and such a process is what consumes up to 90% of the energy and time of the AI deep-learning process. By contrast, the AI chip developed by the NTHU team mimics neuronal synapses, allowing it to perform computations in the memory, which greatly improves efficiency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200304005029/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
